Vanessa Margaret McMahan, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Methamphetamine | 6 | 2024 | 159 | 3.000 |
Why?
|
Homosexuality, Male | 26 | 2020 | 1236 | 2.040 |
Why?
|
Anti-HIV Agents | 30 | 2024 | 4406 | 1.810 |
Why?
|
Drug Users | 3 | 2022 | 131 | 1.430 |
Why?
|
HIV Infections | 43 | 2024 | 16937 | 1.350 |
Why?
|
Medication Adherence | 14 | 2024 | 2113 | 1.080 |
Why?
|
Amphetamine-Related Disorders | 3 | 2024 | 74 | 0.930 |
Why?
|
Washington | 5 | 2024 | 311 | 0.780 |
Why?
|
Peer Group | 3 | 2024 | 649 | 0.740 |
Why?
|
Substance Abuse, Intravenous | 2 | 2022 | 528 | 0.670 |
Why?
|
Deoxycytidine | 10 | 2014 | 843 | 0.620 |
Why?
|
Adenine | 10 | 2014 | 976 | 0.570 |
Why?
|
Opioid-Related Disorders | 4 | 2023 | 2089 | 0.480 |
Why?
|
Substance-Related Disorders | 4 | 2023 | 4294 | 0.420 |
Why?
|
Chemoprevention | 4 | 2015 | 325 | 0.410 |
Why?
|
Condoms | 4 | 2017 | 310 | 0.380 |
Why?
|
Anti-Retroviral Agents | 5 | 2019 | 1756 | 0.370 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2020 | 3896 | 0.330 |
Why?
|
Sexual Behavior | 6 | 2024 | 2045 | 0.300 |
Why?
|
Health Promotion | 2 | 2019 | 2189 | 0.300 |
Why?
|
Communication | 1 | 2020 | 3783 | 0.260 |
Why?
|
Analgesics, Opioid | 8 | 2023 | 3669 | 0.220 |
Why?
|
Sexual Partners | 5 | 2018 | 734 | 0.210 |
Why?
|
HIV Seropositivity | 4 | 2023 | 959 | 0.200 |
Why?
|
Heroin Dependence | 1 | 2022 | 173 | 0.200 |
Why?
|
Adult | 39 | 2024 | 214969 | 0.200 |
Why?
|
Disease Transmission, Infectious | 2 | 2018 | 556 | 0.190 |
Why?
|
Syringes | 1 | 2020 | 57 | 0.180 |
Why?
|
Bone Density | 3 | 2019 | 3510 | 0.180 |
Why?
|
Colorado | 1 | 2020 | 164 | 0.170 |
Why?
|
Oregon | 1 | 2020 | 146 | 0.170 |
Why?
|
Male | 44 | 2024 | 351098 | 0.160 |
Why?
|
Cocaine | 2 | 2021 | 982 | 0.160 |
Why?
|
San Francisco | 4 | 2023 | 161 | 0.150 |
Why?
|
Harm Reduction | 1 | 2019 | 139 | 0.150 |
Why?
|
Antiviral Agents | 3 | 2014 | 3013 | 0.140 |
Why?
|
Self Disclosure | 1 | 2017 | 246 | 0.140 |
Why?
|
Young Adult | 21 | 2020 | 57114 | 0.140 |
Why?
|
Humans | 54 | 2024 | 746070 | 0.130 |
Why?
|
Videoconferencing | 1 | 2018 | 194 | 0.130 |
Why?
|
Cocaine-Related Disorders | 1 | 2019 | 453 | 0.130 |
Why?
|
Prescriptions | 1 | 2018 | 382 | 0.130 |
Why?
|
Thailand | 4 | 2017 | 287 | 0.130 |
Why?
|
Directive Counseling | 2 | 2015 | 167 | 0.120 |
Why?
|
Neuralgia | 1 | 2021 | 574 | 0.120 |
Why?
|
Middle Aged | 21 | 2024 | 214419 | 0.110 |
Why?
|
Bone Diseases | 1 | 2017 | 413 | 0.110 |
Why?
|
Social Stigma | 1 | 2020 | 704 | 0.110 |
Why?
|
Female | 30 | 2024 | 382129 | 0.100 |
Why?
|
Herpesvirus 2, Human | 1 | 2014 | 190 | 0.100 |
Why?
|
HIV-1 | 4 | 2015 | 6870 | 0.100 |
Why?
|
Health Education | 1 | 2019 | 1045 | 0.100 |
Why?
|
Spine | 1 | 2019 | 1092 | 0.100 |
Why?
|
Patient Selection | 1 | 2024 | 4192 | 0.100 |
Why?
|
Kidney Function Tests | 1 | 2014 | 664 | 0.100 |
Why?
|
Transsexualism | 2 | 2012 | 176 | 0.100 |
Why?
|
Drug Resistance, Viral | 2 | 2014 | 837 | 0.100 |
Why?
|
Syphilis | 1 | 2014 | 235 | 0.100 |
Why?
|
Hepatitis B, Chronic | 1 | 2016 | 401 | 0.100 |
Why?
|
Absorptiometry, Photon | 4 | 2019 | 1730 | 0.100 |
Why?
|
Risk-Taking | 1 | 2017 | 983 | 0.100 |
Why?
|
Kidney | 2 | 2019 | 6984 | 0.100 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1177 | 0.090 |
Why?
|
Telemedicine | 2 | 2018 | 2892 | 0.090 |
Why?
|
Antipsychotic Agents | 1 | 2024 | 3054 | 0.090 |
Why?
|
Herpes Simplex | 1 | 2014 | 470 | 0.090 |
Why?
|
Patient Participation | 1 | 2019 | 1412 | 0.090 |
Why?
|
Immunity, Cellular | 1 | 2015 | 1548 | 0.080 |
Why?
|
Sexually Transmitted Diseases | 1 | 2014 | 606 | 0.080 |
Why?
|
Leukocytes, Mononuclear | 1 | 2015 | 1821 | 0.080 |
Why?
|
Administration, Oral | 4 | 2018 | 3966 | 0.070 |
Why?
|
Depression | 2 | 2016 | 7826 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2020 | 3189 | 0.070 |
Why?
|
South Africa | 3 | 2017 | 1748 | 0.070 |
Why?
|
Chicago | 2 | 2018 | 236 | 0.070 |
Why?
|
Placebos | 3 | 2015 | 1658 | 0.070 |
Why?
|
South America | 2 | 2017 | 182 | 0.070 |
Why?
|
Self Report | 2 | 2016 | 3589 | 0.060 |
Why?
|
Qualitative Research | 3 | 2023 | 2840 | 0.060 |
Why?
|
Health Personnel | 1 | 2018 | 3214 | 0.060 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2008 | 871 | 0.060 |
Why?
|
Interviews as Topic | 3 | 2018 | 2602 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 2 | 2015 | 3058 | 0.060 |
Why?
|
Emergency Services, Psychiatric | 1 | 2024 | 69 | 0.060 |
Why?
|
Psychoses, Substance-Induced | 1 | 2024 | 95 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2019 | 848 | 0.060 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2012 | 2204 | 0.060 |
Why?
|
Heroin | 1 | 2022 | 116 | 0.050 |
Why?
|
Substance Abuse Detection | 1 | 2023 | 286 | 0.050 |
Why?
|
Double-Blind Method | 4 | 2018 | 12208 | 0.050 |
Why?
|
Adolescent | 10 | 2023 | 86212 | 0.050 |
Why?
|
United States | 5 | 2020 | 70368 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2023 | 14114 | 0.040 |
Why?
|
Risk Factors | 4 | 2020 | 72413 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2015 | 4518 | 0.040 |
Why?
|
Fentanyl | 1 | 2022 | 411 | 0.040 |
Why?
|
Cohort Studies | 5 | 2021 | 40505 | 0.040 |
Why?
|
False Negative Reactions | 1 | 2020 | 572 | 0.040 |
Why?
|
Safe Sex | 1 | 2018 | 138 | 0.040 |
Why?
|
Social Identification | 1 | 2018 | 103 | 0.040 |
Why?
|
Hip | 1 | 2019 | 249 | 0.040 |
Why?
|
False Positive Reactions | 1 | 2020 | 953 | 0.040 |
Why?
|
Violence | 1 | 2023 | 912 | 0.040 |
Why?
|
Personal Satisfaction | 1 | 2021 | 636 | 0.040 |
Why?
|
Boston | 2 | 2023 | 9209 | 0.040 |
Why?
|
Ecuador | 1 | 2015 | 54 | 0.030 |
Why?
|
Central Nervous System Stimulants | 1 | 2024 | 1157 | 0.030 |
Why?
|
Human Immunodeficiency Virus Proteins | 1 | 2015 | 63 | 0.030 |
Why?
|
Incidence | 4 | 2014 | 20812 | 0.030 |
Why?
|
Specimen Handling | 1 | 2020 | 694 | 0.030 |
Why?
|
Phosphorous Acids | 1 | 2014 | 4 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2016 | 519 | 0.030 |
Why?
|
Patient Compliance | 2 | 2017 | 2666 | 0.030 |
Why?
|
RNA, Viral | 2 | 2014 | 2818 | 0.030 |
Why?
|
Awareness | 1 | 2018 | 644 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2014 | 363 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2023 | 5093 | 0.030 |
Why?
|
Phosphorus | 1 | 2014 | 325 | 0.030 |
Why?
|
Blood Chemical Analysis | 1 | 2014 | 433 | 0.030 |
Why?
|
Peru | 1 | 2015 | 847 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2016 | 964 | 0.030 |
Why?
|
Plasma | 1 | 2015 | 574 | 0.020 |
Why?
|
Brazil | 1 | 2015 | 1192 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2012 | 6459 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1894 | 0.020 |
Why?
|
Cytoplasm | 1 | 2015 | 1522 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2017 | 1410 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2016 | 1162 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 2018 | 1876 | 0.020 |
Why?
|
Aged | 6 | 2018 | 164222 | 0.020 |
Why?
|
Public Health | 1 | 2022 | 2624 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2021 | 3408 | 0.020 |
Why?
|
vif Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 54 | 0.020 |
Why?
|
Creatinine | 1 | 2014 | 1848 | 0.020 |
Why?
|
Drug Utilization | 1 | 2014 | 1172 | 0.020 |
Why?
|
Adiposity | 1 | 2018 | 1822 | 0.020 |
Why?
|
Focus Groups | 1 | 2013 | 1336 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25174 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2017 | 38752 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3782 | 0.020 |
Why?
|
Nausea | 1 | 2010 | 668 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2015 | 919 | 0.020 |
Why?
|
Epitope Mapping | 1 | 2008 | 305 | 0.020 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 220 | 0.020 |
Why?
|
Body Weight | 1 | 2018 | 4590 | 0.020 |
Why?
|
Lipids | 1 | 2018 | 3290 | 0.020 |
Why?
|
Prevalence | 2 | 2014 | 15306 | 0.020 |
Why?
|
Health Policy | 1 | 2019 | 2648 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2019 | 63664 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2015 | 3134 | 0.020 |
Why?
|
Internet | 1 | 2018 | 3038 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7673 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10278 | 0.020 |
Why?
|
Viral Load | 1 | 2014 | 3297 | 0.020 |
Why?
|
Pilot Projects | 1 | 2018 | 8370 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2015 | 5837 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14537 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5236 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3820 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2023 | 78293 | 0.010 |
Why?
|
HIV Antibodies | 1 | 2010 | 1289 | 0.010 |
Why?
|
HIV | 1 | 2010 | 1585 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2015 | 4296 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7272 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12018 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7699 | 0.010 |
Why?
|
Body Mass Index | 1 | 2018 | 12633 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13164 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6453 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12775 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 23454 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 21676 | 0.010 |
Why?
|
Cytokines | 1 | 2008 | 7219 | 0.010 |
Why?
|
Pregnancy | 1 | 2013 | 29296 | 0.010 |
Why?
|
Mutation | 1 | 2014 | 29620 | 0.010 |
Why?
|